Public Companies
Atai CEO Answers Questions From the Public
The article Atai CEO Answers Questions From the Public was originally published on Microdose.
Reddit is the internet incarnate. From time-wasting memes,…
The article Atai CEO Answers Questions From the Public was originally published on Microdose.
Reddit is the internet incarnate. From time-wasting memes, to basement-troll commentary, to informative opinions on the day’s biggest issues – it showcases everything the web has to offer in one place.
This week, r/shroomstocks hosted an AMA (Ask Me Anything) with Florian Brand and Srinivas Rao, Co-Founders and CEO and CSO of atai Life Sciences.
The public forum took place on Shroomstocks, a Reddit community of nearly 60,000 members interested in the psychedelics industry and investments. The questions poured in and over the course of the week, the atai team answered as many as they could get to (or wanted to).
We sifted through the pages to bring you some of the more important replies, giving some context on atai’s programs and plans.
One of the most popular questions was about PCN-101, the ketamine compound that had less than positive Phase 2 results.
Then onto KUR-101 and its trial on Opioid Use Disorder.
Re: Patents. Apparently, there’s a lot on them. With 32 issued in the US and 273 internationally.
atai initiated a Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia. The trial was initiated and has begun patient screening. There are currently no FDA-approved medications for CIAS, a major cause of disability in 80% of patients with schizophrenia.
atai and its collaborators have sometimes been accused of aggressive or even unethical patent strategies. They’re considered by some to be the most hyper-capitalist of the major players. Here they address some more qualitative aspects of their business.
And finally, on the future of FDA approval and the benefits of controlled therapeutic treatment vs recreational.
For more on atai, check out a deeper look at their recent corporate update
ketamine psychedelics atai atai life sciences fda-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment